



2025 MGFA SCIENTIFIC SESSION Program

2025 AANEM Annual Meeting | Wednesday, October 29, 2025 | San Francisco, CA



Myasthenia Gravis Foundation of America provides a platform for clinical and scientific experts to share current and prospective peer-reviewed research focused on myasthenia gravis and related disorders of the neuromuscular junction. The MGFA Scientific Session includes presentations highlighting the latest advancements in our understanding of MG etiology, pathogenesis, therapeutic developments, and management.

Thank you to our Steering Committee

**Tuan Vu, MD • Gianvito Masi, MD • Neelam Goyal, MD • Colleen Noviello, PhD
Ali Habib, MD • Kelly Gwathmey, MD • Richard Nowak, MD, MS**

2025 MGFA Scientific Session Agenda

Please enjoy a light breakfast and coffee breaks throughout the morning, brought to you by our partner Alexion.

Session A

Welcome and Keynote

8:00 - 8:05am:	Welcome – Samantha Masterson, President and CEO, MGFA
8:06 - 8:11am:	Introduction of Keynote – Richard Nowak, MD, MS
8:12 - 8:52am:	Keynote Address: Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures – Ryan Hibbs, PhD
8:53 - 8:59am:	Q&A – Moderator Ali Habib, MD

Biomarkers and Basic Science

9:00 - 9:08am:	Disease Specific Protein Biomarkers in Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis – Anna Punga, MD, PhD
9:09 - 9:17am:	Presentation of Shed Acetylcholine Receptors from Damaged Muscles Triggers Myasthenia Gravis in Rats – Jie Luo, PhD
9:18 - 9:26am:	S-1117, an Engineered Pan-IgG Cleaving Enzyme, Reduces IgG BCR Mediated B Cell Activation and Eliminates Intact Anti-AChR IgG Tissue Deposition in an MG Mouse Model – Liliana Sanmarco, PhD
9:27 - 9:35am:	Q&A – Moderator Ali Habib, MD
9:35 - 10:00am:	Coffee Break

Session B

Therapeutics and Clinical Trials

10:00 - 10:09am:	Phase III Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy Data in AChR+ Generalized MG Subpopulation Through Week 52 – Richard Nowak, MD, MS
10:10 - 10:19am:	Long-term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-label Extension Phase Results – Tuan Vu, MD
10:20 - 10:29am:	Results from the ADAPT JR Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis – Abigail Schwaede, MD
10:30 - 10:39am:	Safety and Efficacy Results of Nipocalimab in Adolescents with Generalized Myasthenia Gravis During Active-Treatment and Long-Term Extension phases: Vibrance-MG Phase II/III Study – Jonathan Strober, MD
10:40 - 10:49am:	Phase III Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis – James F. Howard Jr., MD
10:50 - 10:59am:	Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase III Study – George Li, MD
11:00 - 11:09am:	Update on the Phase II Part of KYSA-6, an Open-Label, Single-Arm, Multicenter Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor T-Cell Therapy in Generalized Myasthenia Gravis – Srikanth Muppidi, MD
11:10 - 11:19am:	Efficacy and Safety of Autologous BCMA-Directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: 12-Month Follow-Up of a Phase 2B Randomized Placebo-Controlled Trial – Tuan Vu, MD
11:20 - 11:29am:	Top Line Results for MAGIC, a Phase II Trial of DNTH103, an Active C1S Inhibitor, in Generalized Myasthenia Gravis – Pushpa Narayanaswami, MD

11:30 – 11:39am:	Efficacy and Safety of Subcutaneous Self-Administered Gefurulumab in Generalized Myasthenia Gravis (PREVAIL): Topline Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study – Kelly Gwathmey, MD
11:40 – 11:45am:	Q&A – Moderator Neelam Goyal, MD
11:46 – 1:00pm:	Lunch (Not served at MGFA Scientific Session – On Your Own)

Session C

Patient Care, Hot Topics, Retrospective/Post-Hoc Studies

Theme: Corticosteroids

1:00 – 1:07pm:	Longitudinal Associations of Corticosteroid Dose with Corticosteroid Toxicity in Patients with Myasthenia Gravis in the USA – Thomas Ragole, MD
1:08 – 1:15pm:	Corticosteroid Dose Tapering during Treatment with Rozanolixizumab in Patients with Generalized Myasthenia Gravis: Post Hoc Analysis – Robert Pascuzzi, MD
1:16 – 1:23pm:	Reduction in Oral Glucocorticoid Use at 18 Months Following Efgartigimod Initiation Based on a United States Claims Database – Neelam Goyal, MD
1:24 – 1:31pm:	Q&A – Moderator Tuan Vu, MD

Theme: Meningococcal Infection/Immunization

1:32 – 1:39pm:	Characterization of Antibiotic Prophylaxis Risk Mitigation Practices Across Eculizumab and Ravulizumab Adult, Phase III Clinical Trials for PNH, AHUS, GMG and NMOSD – Lokesh Jha, MD
1:40 – 1:47pm:	Incidence and Outcome of Meningococcal Infection with Eculizumab or Ravulizumab in Patients with Generalized Myasthenia Gravis or Neuromyelitis Optica Spectrum Disorder: An Updated Analysis – Shirali Pandya, PhD
1:48 – 1:55pm:	Q&A – Moderator Richard Nowak, MD, MS

Theme: Diagnosis, Diagnostics, and Management Considerations

1:56 – 2:03pm:	Impact of Botulinum Toxin on the Electrophysiology of Ocular Myasthenia Gravis: A Case Series – Juan Camilo Ibarra-Jurado, MD
2:04 – 2:11pm:	Diaphragmatic Compound Muscle Action Potentials Correlate with the Clinical Severity of Myasthenia Gravis – Hiroto Suenaga, MD, PhD
2:12 – 2:19pm:	The Evolving Treatment Landscape in Myasthenia Gravis: The Value of Shared Decision Making – James F. Howard Jr., MD
2:20 – 2:27pm:	Q&A – Moderator Ali Habib, MD
2:28 – 2:30pm:	Final Remarks and Wrap Up – Danielle M. Kerkovich, PhD, VP for Global Research, MGFA
2:30 – 3:30pm:	MGFA Scientific Session Poster Session (Plaza A/B)



MGFA Scientific Session Poster Directory

View posters downstairs in Plaza A/B. Be sure to stop by the Poster Session from 2:30 - 3:30 p.m. to talk with the investigators. Posters are only available to view on Wednesday, October 29.

A list of posters is available starting on page 5 as well as on the MGFA's website. View all abstracts on the MGFA's website via the QR code shared below, or visit the event webpage at myasthenia.org.

PLAZA A/B

168	167	166	165	164	163	162	161	160	159	158	157	156	155
141	142	143	144	145	146	147	148	149	150	151	152	153	154
140	139	138	137	136	135	134	133	132	131	130	129	128	127
113	114	115	116	117	118	119	120	121	122	123	124	125	126
112	111	110	109	108	107	106	105	104	103	102	101	100	99
85	86	87	88	89	90	91	92	93	94	95	96	97	98

	TABLE	TABLE	TABLE
--	-------	-------	-------

TABLE	TABLE	TABLE	
-------	-------	-------	--

84	83	82	81	80	79	78	77	76	75	74	73	72	71
57	58	59	60	61	62	63	64	65	66	67	68	69	70
56	55	54	53	52	51	50	49	48	47	46	45	44	43
29	30	31	32	33	34	35	36	37	38	39	40	41	42
28	27	26	25	24	23	22	21	20	19	18	17	16	15
1	2	3	4	5	6	7	8	9	10	11	12	13	14



Poster #	First Name	Last Name	Poster Title
1	Sarah	Abdul-Ghani	Investigating the Prevalence of Myasthenia Gravis and Parkinson Disease Co-occurrence in the United States in 2022
2	Seth	Anderson	Relationship between Disease Burden and Healthcare Expenditure among Patients with Generalized Myasthenia Gravis (GMG) in the United States: A Retrospective Database Analysis
3	Yaacov	Anziska	Patient Characteristics and Time to Stable Dose with Amifampridine Phosphate in the Treatment of Lambert Eaton Myasthenic Syndrome in the United States
4	Yaacov	Anziska	The Impact of Race and Income on Myasthenia Gravis Management and Outcomes
5	Mert	Aral	Gathering Real World Insights from People Living with Myasthenia Gravis: Analysis of User Characteristics and Adherence Patterns in Patients Using the Humamg App
6	Priyanshu	Bansal	Steroid-sparing Benefits of Ravulizumab in Refractory Myasthenia Gravis: A Real-world Retrospective Analysis
7	Carolina	Barnett-Tapia	Measuring the Effect of Rozanolixizumab Treatment in the Mycaring Study Using the Myasthenia Gravis Impairment Index
8	Alexandra C.	Bayer	Immunoglobulin-specific Proteases Disarm Pathogenic Acetylcholine Receptor-specific Autoantibodies in Myasthenia Gravis
9	Said R.	Beydoun	Composite Response to Nipocalimab Based on Both Myasthenia Gravis Activity of Daily Living and Quantitative Myasthenia Gravis Scores in Patients with Generalized Myasthenia Gravis
10	Shamik	Bhattacharyya	Predictors of Myasthenia Gravis Hospitalizations in the Predict Study
11	Ratna	Bhavaraju-Sanka	Adherence to and Persistence with Biologics among U.S. Patients with Generalized Myasthenia Gravis: A Claims-based Study
12	Michael	Blackowicz	Impact on Healthcare Resource Utilization in Early Initiators of Ravulizumab or Efgartigimod for Treatment of Generalized Myasthenia Gravis in the U.S.A.
13	Vera	Brit	Long-term Safety of Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Final Analysis of Phase 3 Studies
14	Vern	C. Juel	Design of a Phase 3 Randomized, Double-blinded, Placebo-controlled Study Evaluating Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults with Ocular Myasthenia Gravis
15	Francisco	Caiza-Zambrano	Delay in the Diagnosis of Myasthenia Gravis. A Multicentric Retrospective Study in Argentina.
16	Nolan	Campbell	Design of a Digital Solution to Improve Myasthenia Gravis Patient Symptom Tracking in Routine Clinical Care
17	Nolan	Campbell	Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3B, Interventional Trial Including within Class Switching from Efgartigimod to Nipocalimab (EPIC): Study Design
18	Nolan	Campbell	Identifying Risk Factors for Exacerbation and Symptom Worsening—A Retrospective Cohort Study of Patients with Myasthenia Gravis in the United States
19	Kangzhi	Chen	Development and Validation of Autoantigen-expressing Stable Cell Lines for Autoantibody Characterization in Autoimmune Neurological Disorders
20	Zia	Choudhry	Mapping Out the Patient Journey of Generalized Myasthenia Gravis: Insights and Challenges
21	Ailian	Du	Muscle Carbonic Anhydrase 3 Inhibits Complement C3A-mediated Follicular Helper T Cell Differentiation.

Poster #	First Name	Last Name	Poster Title
22	OluYemisi	Falope	Patient and Caregiver Experiences of Symptom Instability and Unpredictability from a Myasthenia Gravis Patient Engagement Research Council: A Generative AI-assisted Analysis
23	Constantine	Farmakidis	Assessing Severity in Generalized Myasthenia Gravis: A Phase 3 Study of Nipocalimab Using Quantitative Myasthenia Gravis Items and Domains
24	Cherine	Fawaz	Impact of Thymectomy in the Older Myasthenia Gravis (MG) Patients.
25	Miriam	Freimer	Zilucoplan Treatment of Severe Exacerbations Leading to Hospitalization in Generalized Myasthenia Gravis: Study Design
26	Miriam	Freimer	The Long-Term Effectiveness of Zilucoplan in Myasthenia Gravis: Predictive Modeling in a US Real-world Database
27	Kavita	Gandhi	Hospital Resource Utilization Associated with Nipocalimab versus Placebo: Post-hoc Analysis of the Vivacity-MG3 Trial in Generalized Myasthenia Gravis
28	Rachana K.	Gandhi Mehta	Manual Push Administration of Rozanolixizumab in Generalized Myasthenia Gravis
29	Sheng	Gao	Post-hoc Analysis of Clinically Relevant Anti-vaccine and Anti-virus Antibodies in Patients Treated with Nipocalimab in Vivacity-MG3 Study
30	Malin	Garrett	Single-fiber EMG Reveals Neuromuscular Transmission Disturbances in Pediatric Prader-Willi Syndrome: A Diagnostic Consideration in Myasthenic Disorders
31	Andrew	Gordon	An Analysis of Digital Conversations to Understand Patient Perceptions of the Dosing and Administration of Neonatal FC Receptor Inhibitors for Treatment of Myasthenia Gravis
32	Kavita	Grover	Factors Associated with Exacerbations or Crises in Generalized Myasthenia Gravis
33	Amanda	Guidon	Physical Activity and Factors Associated with Exercise Participation among Individuals in the MGFA Patient Registry
34	Kelly	Gwathmey	Usability of Gefurulimab Autoinjector (AI) and Prefilled Syringe (PFS) Devices: A Human Factors Validation Study
35	Ali A.	Habib	Reset-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis
36	Ali A.	Habib	Repeated Cycles of Rozanolixizumab Treatment in Patients with Anti-muscle-specific Tyrosine Kinase Antibody-positive Generalized Myasthenia Gravis
37	Spencer	Hall	Efgartigimod Use in a Pregnant Female with Myasthenia Gravis
38	Kristin	Heerlein	High Cardiovascular Disease Burden among Patients with Myasthenia Gravis in US
39	Irum	Hina	Rituximab for Refractory Seropositive Myasthenia Gravis (MG)
40	Brant	Hubbard	Differences between Patient and Provider Perceptions in Assessing Myasthenia Gravis Disease Burden and Minimal Symptom Expression: A Real-world Survey
41	Tom	Hughes	Comparative Analysis of Patient Social Media Sentiment for Vyvgart in GMG Compared to Treatments in Other Complex Disease Areas
42	Tom	Hughes	Assessing Social Media Sentiment to Analyze Patient, Caregiver and Healthcare Professionals Experience with Vyvgart and Vyvgart Hytrulo for Generalized Myasthenia Gravis
43	Hans	Katzberg	Safety Profile of Nipocalimab, a New Neonatal Fragment Crystallizable Receptor Blocker in the Phase 3 Vivacity-MG3 Study

Poster #	First Name	Last Name	Poster Title
44	Jasmeet	Kaur	Concomitant Use of Complement and FCRN Inhibitors for Management of Refractory Acetylcholine Receptor (AChR) Antibody Positive Generalized Myasthenia Gravis (MG)
45	Fatemeh	Khani-Habibabadi	The Effect of Efgartigimod on AChR-AB Mediated Pathogenic Mechanisms in Patients with GMG
46	Austin	Kulasekararaj	Eculizumab-AEEB Biosimilar to Eculizumab Reference: Product – Pharmacokinetic / Pharmacodynamic Data to Further Support Clinical Similarity and Scientific Justification for Extrapolation
47	Mohita	Kumar	Characteristics of Patients with Generalized Myasthenia Gravis Initiating Rozanolixizumab Treatment in the United States
48	Kunkala	Lavanya	"Antibodies at Play: A Neurologist's Rollercoaster Ride with Triple Positive Myasthenia"
49	Mao	Liu	The Effects of Six-month Intervention on the Attitude towards Myasthenia Gravis and Neuromuscular Disease among Neurology Residents
50	Alexis	Lizarraga	Retrospective Analysis of Efficacy and Outcomes of Daily versus Alternate Day Plasma Exchange in Myasthenic Crisis: A Single Center Experience
51	Jie	Luo	Structural Insights into the Hexamerization and Complement Activation of a Human Anti-acetylcholine Receptor Antibody
52	Alanna	McEneny	Phase 1 Study Evaluating Gefurumab Pharmacokinetics and Safety Following Delivery via Autoinjector or Prefilled Syringe in Healthy Adults
53	Zainab	Memon	Early Use of Rituximab in Myasthenia Gravis in a Resource-limited Setting: A Retrospective Cohort Study from a Tertiary Center in Pakistan
54	J. Douglas	Miles	A Case of Treatment with Efgartigimod PH20 SC in a Patient with Ocular Myasthenia Gravis
55	Lesley-Ann	Miller-Wilson	Treatment Utilization and Clinical Outcomes by Serostatus in a Real-world US Generalized Myasthenia Gravis Population
56	Lesley-Ann	Miller-Wilson	Physician, Patient, and Caregiver Concordance in a Real-world US Generalized Myasthenia Gravis Population
57	Lesley-Ann	Miller-Wilson	Physician- and Patient-reported Outcomes by Disease Severity in a United States Real-world Myasthenia Gravis Population
58	Mauricio	Muñoz Mojica	Beyond Polyneuropathy: The Classic Electrodiagnostic Triad and Antibody Detection for the Diagnosis of Presynaptic Myasthenic Syndrome (Lambert-Eaton).
59	Pushpa	Narayanaswami	The All-encompassing Role of Caring for People with Generalized Myasthenia Gravis (GMG): A Qualitative Study of Caregiver Experiences
60	Pushpa	Narayanaswami	Understanding the Lived Experiences of People with Generalized Myasthenia Gravis and the Impact on Daily Life: A Mixed Methods Study
61	Richard J.	Nowak	Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52)
62	Martina	Orlovic	Disease Burden, Impact on Daily Functioning, and Psychological Well-being in Patients with Ocular Myasthenia Gravis: Insights from a U.S. Patient Panel
63	Martina	Orlovic	Diagnosis Journey, Treatment, and Management of Patients with Ocular Myasthenia Gravis: Insights from a U.S. Patient Panel
64	Sheryl	Pease	Fatigue Assessed by Neuro-quality of Life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis
65	Sheryl	Pease	Assessment of Patient-reported Outcomes from the Phase 3 Vivacity-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis
66	Amy	Perrin Ross	Educational Needs Assessment of Nurses Involved in the Care of Patients with Myasthenia Gravis

Poster #	First Name	Last Name	Poster Title
67	Jacqueline	Pesa	Treatment-related Characteristics among Younger Women with Generalized Myasthenia Gravis
68	Jana	Podhorna	Evaluation of Cardiovascular Comorbidity Burden in Patients with Generalized Myasthenia Gravis Treated with Efgartigimod
69	Erik	Procko	Preclinical Evaluation of an Autoantibody Protease for the Treatment of Myasthenia Gravis and Related Autoimmune Diseases
70	Cynthia	Qi	Patient Characteristics, Dosing Patterns, and Outcomes Associated with Intravenous and Subcutaneous Efgartigimod among Patients with Generalized Myasthenia Gravis in Clinical Practice
71	Cynthia	Qi	Drivers of Mortality in Patients with Myasthenia Gravis in the United States National Veterans Affairs Health Care Network and Medicare Databases
72	Cynthia	Qi	Comparative Benefits of Immunomodulatory Therapies for Generalized Myasthenia Gravis
73	Michael	Blackowicz	Corticosteroid Toxicity and Related Healthcare Resource Utilization in Patients with Myasthenia Gravis in the USA
74	Sanjay	Rakhade	Assessing Efficacy and Safety of Gefurulumab in Generalised Myasthenia Gravis: Baseline Characteristics from Preval
75	Rodrigo	Rodriguez	Efgartigimod Monotherapy in ACHR and MUSK Negative MG, with Titin Antibody Positivity: A Case Report
76	Gregory	Sahagian	Impact of Long-term Intravenous Efgartigimod on Quality of Life, Disease Severity, and Safety in Participants with Generalized Myasthenia Gravis during Adapt NXT
77	Sara Francesca	Santagostino	Exploring Accuracy and Utility of Artificial Intelligence in the Real-world Management of Myasthenia Gravis
78	Christopher	Scheiner	Outcomes for Patients Receiving Ravulizumab or Efgartigimod Treatment within Two Years of Generalized Myasthenia Gravis (GMG) Diagnosis: A Retrospective Subanalysis of US Medical Records
79	Abigail	Schwaede	Medically Refractory Autoimmune Myasthenia Gravis in a 6-year-old Girl: Dramatic Response to Efgartigimod via Emergency IND Access
80	Keshav	Shah	Clinical, Immunologic and Therapeutic Correlation between Myasthenia Gravis and Crohn's Disease: A Case Report and Literature Review
81	Meghana	Shownkeen	Combined Use of Zilucoplan and Rituximab for Acetylcholine Receptor Antibody Positive (ACHR+) Generalized Myasthenia Gravis
82	Michael	Slama	Combining Complement Inhibition and Antibody Reduction in Refractory ACHR Generalized Myasthenia Gravis
83	Vu	Trinh	An Antigen-specific Chimeric Autoantibody Receptor T Cell Strategy for the Elimination of Anti-main Immunogenic Region Antibody-secreting B Cells
84	Tuan	Vu	Response to Rozanolixizumab in Patients with Generalized Myasthenia Gravis: Final Pooled Analysis of Mycaring and Open-label Extension Studies
85	Tuan	Vu	Rozanolixizumab Treatment Patterns in Patients with Generalized Myasthenia Gravis: A Post Hoc Analysis of Final Pooled Phase 3 Data
86	Tuan	Vu	Insights into Nipocalimab-neonatal Fragment Crystallizable Receptor Structure, Binding Affinity, and Inhibition of Immunoglobulin G Recycling: Comparison with Efgartigimod
87	Tuan	Vu	Efficacy of Nipocalimab in Open-label Extension in Patients Transitioned from Placebo: Results from Vivacity-MG3 Trial
88	Michael D.	Weiss	Effect of Zilucoplan on Fatigue in Patients with Generalized Myasthenia Gravis: Raise-XT 120-week Follow-up

Poster #	First Name	Last Name	Poster Title
89	Michael D.	Weiss	Interpreting Patient Quality-of-life Experience with Zilucoplan Treatment in Generalized Myasthenia Gravis in Raise and Raise-XT
90	Wade	Whitt	Invisible Markers, Visible Impact: Greater Disease Burden in Seronegative Myasthenia Gravis
91	Sarah	Wright	Demographic and Clinical Predictors of Persistent Ophthalmoplegia in Juvenile Myasthenia Gravis
92	Benjamin	Yungher	Assessing Oral Corticosteroid Tapering in Ravulizumab-treated Adults with Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: The Phase 4, Global Octagon Study Design
93	Yaowei	Zhu	Development of a Whole-body Physiologically-based Pharmacokinetic Model for FCRN Inhibitors in Pregnancy Incorporating Placental Transfer
94	Yaowei	Zhu	Predicting Total Immunoglobulin G Change from Baseline When Switching from Efgartigimod to Nipocalimab
95	Yaowei	Zhu	Nipocalimab Effect on Immunoglobulin G Subclasses in Patients with Generalized Myasthenia Gravis
96	Yaowei	Zhu	Population Pharmacokinetics and Pharmacodynamics Modeling of Nipocalimab in Adolescents Aged 12 to Less than 18 Years with Generalized Myasthenia Gravis
97	Christen	Kutz	Retrospective Analysis of Efgartigimod Alpha-FCAB or Efgartigimod Alpha and Hyaluronidase-GVFC to Ravulizumab in Patients with Myasthenia Gravis (MG)
98	Christen	Kutz	Retrospective Analysis of Intravenous Immunoglobulin (IVIg) Infusion Switches to Ravulizumab (Ultomiris) in Patients with Myasthenia Gravis (MG)

Poster List
& Abstracts



Thank you to our generous sponsors for their ongoing commitment to the MG Community

